Primary central nervous system lymphoma (PCNSL) is an aggressive mature lymphoma of the diffuse-large B cell type which exclusively manifests in the central nervous system compartment. Patients > 60 years compromise > 50% of the PCNSL patients. During the last years progress has been made in prolonging  survival,  reducing  toxicity  and  improving  quality  of  life  for  this  challenging subgroup of patients. But in contrast to the younger patients we are still facing a palliative treatment approach. 
The principal objective of this multicentre, phase II study is to investigate the efficacy of age-adjusted induction treatment followed by high-dose chemotherapy and autologous stem cell transplantation in elderly and fit patients with PCNSL.